One stock that's been on my watch list for a while is CRISPR Therapeutics (NASDAQ: CRSP). The company has an intriguing ...

Since the beginning of 2026, shares of CRISPR Therapeutics (CRSP) are down by about 11%. While that’s not a great start to ...

CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a medicine for a pair of rare blood diseases, which became the first ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value of over $551 million as of Q4 2025. The gene-editing company remains on ...

The gene-editing company said it intends to offer the convertible senior notes due 2031 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.